Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Roche | Emicizumab | Hemlibra | 2018-02-23 | $4,779.09 M | Q4/22-Q3/23 | |
Bayer | Octocog alfa | Helixate NexGen | 2000-08-04 | |||
Octocog alfa | Iblias | 2016-02-18 | ||||
Octocog alfa | Kogenate Bayer | 2000-08-04 | ||||
Octocog alfa | Kovaltry | 2016-02-18 | ||||
Pfizer | Nonacog alfa | BeneFIX | 1997-08-27 | $424 M | Y2023 | |
Moroctocog alfa | ReFacto | 1999-04-13 | $230 M | Y2023 | ||
Takeda | Octocog alfa | Advate | 2004-03-02 | |||
Genentech | Emicizumab | Hemlibra | 2017-11-16 | |||
Orphan Medical | Efmoroctocog alfa | Elocta | 2015-11-18 | |||
Novo Nordisk | Turoctocog alfa | Esperoct | 2019-06-20 | |||
Turoctocog alfa | NovoEight | 2013-11-13 | ||||
Eptacog alfa (activated) | NovoSeven | 1996-02-23 | ||||
BioMarin Pharmaceutical | Valoctocogene roxaparvovec | Roctavian | 2023-06-29 | $16.338 M | Q3/23-Q3/24 | |
CSL Behring | Lonoctocog alfa | Afstyla | 2017-01-04 | |||
Human coagulation factor viii, Human von willebrand factor | Voncento | 2013-08-12 |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|